Floatz logo

Carboplatin

B-Cell Non-Hodgkin Lymphoma

Explore 306 assets in B-Cell Non-Hodgkin Lymphoma →
Floatz Rating
BB68/100
Confidence
Indicative
v0.2
Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07081022CT.gov
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
—Recruiting———
NCT05991388CT.gov
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
—Recruiting———
NCT06230224CT.gov
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
—Active Not Recruiting———
NCT05464329CT.gov
Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
—Active Not Recruiting———
NCT05533775CT.gov
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
—Recruiting———
NCT04665765CT.gov
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
—Active Not Recruiting———
NCT02592876CT.gov
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
—Terminated———
NCT00891072CT.gov
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
—Completed———
NCT00515138CT.gov
A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant
—Terminated———
NCT01300793CT.gov
Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide
—Terminated———
Show 1 more trial
NCT00588094CT.gov
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · B-Cell Non-Hodgkin Lymphoma

AssetSponsorPhaseRating
Carboplatin (this asset)Shanghai Junshi Bioscience Co., Ltd.P3BB · 68
VindesineChildren's Cancer Group, ChinaP4BBB
Anti-Cd20/Cd3 Monoclonal Antibody Regn1979University of BirminghamP3BBB
CytarabineChildren's Cancer Group, ChinaP4BBB
ZanubrutinibThe First Affiliated Hospital of Soochow UniversityP4BBB
IsocyclophosphamideShanghai Junshi Bioscience Co., Ltd.P4BBB
CamustineFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyP4BBB
Autologous Cd4+ And Cd8+ T Cells, Enriched From Peripheral Blood Mononuclear Cells (Pbmcs) Transduced With A Nonreplicative Self-Inactivating (Sin) Lentiviral Vector Encoding A Chimeric Antigen Receptor (Car) Consisting Of The Human Cd19-Specific Scfv, An Lgg4 Hinge Region, Cd28 Transmembrane Domain, Cd137 (4-1Bb) Co-Stimulatory Domain And Cd3 Zeta Signalling Domain, Under The Control Of A Hybrid Elongation Factor 1 Alpha (Ef1.Alpha.) And Human T Cell Leukemia Virus Type 1(Htlv-1) Regulatory Element Promoter And Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Element (Wpre). The Vector Genome Also Encodes A Truncated Human Epidermal Growth Factor Receptor (Egfrt) That Is Co-Expressed With The Car And Cleaved From It By The T2A Self-Cleaving Peptide. The Vector Genome Also Contains A Splice Donor, A Fragment Of Gag, A Rev Response Element (Rre), A Mutated Central Polypurine Tract (Cppt), And A Splice AcceptorRuijin HospitalP4BBB
TacrolimusM.D. Anderson Cancer CenterP2BB

+42 more in the B-Cell Non-Hodgkin Lymphoma cohort

Other indications for Carboplatin

IndicationSponsorPhaseRating
Lung Large Cell Carcinoma—P4A · 80
Primary Peritoneal Carcinoma—P3BBB · 76
Non-Small Cell Squamous Lung Carcinoma—P3BBB · 76

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Carboplatin in B-Cell Non-Hodgkin Lymphoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/carboplatin-b-cell-non-hodgkin-lymphoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →